Your search for dabigatran returned 89 results

Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated to reduce the risk of stroke and blood clots.

The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.

Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source

Researchers performed a retrospective cohort study to compare incidence of stroke, bleeding, and myocardial infarction in patients with atrial fibrillation initiating dabigatran or warfarin (n=25,289 for each) from November 2010 to May 2014.

Effective for dabigatran reversal among patients with uncontrolled bleeding, undergoing urgent surgery

Combining dabigatran with certain statin medications could raise the odds for major hemorrhage in patients with atrial fibrillation, according to a study published online in CMAJ, the journal of the Canadian Medical Association.

Increase in risk of intracranial hemorrhage, major GI bleeding in a-fib patients taking rivaroxaban

Boehringer Ingelheim has announced that Praxbind, a reversal agent for the oral anticoagulant Pradaxa (dabigatran etexilate mesylate), is now available in over 2,200 hospitals across the U.S

Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding

Despite trend toward lower stroke risk with high dose